Source - RNS
RNS Number : 7108F
Hikma Pharmaceuticals Plc
19 May 2017
 

 

Hikma Pharmaceuticals PLC

Voting Results of 2017 Annual General Meeting

LONDON, 19 May 2017 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 19 May 2017 commenced at 10:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 19 were passed as ordinary resolutions and Resolutions 20 to 23 were passed as special resolutions.

As previously announced, Mr. Michael Ashton retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility. 

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2017) is set out below. The number of Ordinary Shares in issue on 19 May 2017 was 240,380,475.

Resolution

Votes For

%

Votes Against

%

Withheld

Total Cast

1. To receive the 2016 report and accounts

197,423,759

99.84%

319,920

0.16%

6,643

197,750,322

2. To approve a final dividend of 22 cents per share

197,743,879

100.00%

0

0.00%

6,443

197,750,322

3. To re-appoint PricewaterhouseCoopers LLP as auditors

197,741,251

100.00%

905

0.00%

8,166

197,750,322

4.To authorise the Audit Committee to determine the auditors' remuneration

197,688,953

99.97%

53,203

0.03%

8,166

197,750,322

5. To elect Nina Henderson as a director

197,534,627

99.89%

208,786

0.11%

6,854

197,750,267

6. To re-elect Said Darwazah as a director

193,519,353

98.05%

3,848,526

1.95%

382,442

197,750,321

7. To re-elect Mazen Darwazah as a director

195,813,592

99.21%

1,551,895

0.79%

384,835

197,750,322

8. To re-elect Robert Pickering as a director

197,076,319

99.66%

667,559

0.34%

6,443

197,750,321

9.To re-elect Ali Al-Husry as a director

196,769,085

99.57%

857,947

0.43%

123,290

197,750,322

10. To re-elect Dr. Ronald Goode as a director

195,703,815

98.97%

2,039,923

1.03%

6,584

197,750,322

11. To re-elect Patrick Butler as a director

197,506,890

99.88%

236,848

0.12%

6,584

197,750,322

12. To re-elect Dr. Jochen Gann as a director

196,795,912

99.58%

830,979

0.42%

123,431

197,750,322

13. To re-elect John Castellani as a director

197,586,602

99.92%

157,277

0.08%

6,443

197,750,322

14. To re-elect Dr. Pamela Kirby as a director

195,665,777

98.96%

2,053,602

1.04%

6,468

197,725,847

15. To approve the directors' remuneration policy

169,053,856

86.39%

26,622,257

13.61%

2,074,207

197,750,320

16. To approve the remuneration report for the year ended 31 December 2016

193,651,599

97.93%

4,091,754

2.07%

6,968

197,750,321

17. To approve the extension of the effective period of the Executive Incentive Plan

170,276,525

86.12%

27,450,966

13.88%

22,830

197,750,321

18. To approve the increase of the aggregate directors' fee limit

197,640,307

99.98%

45,091

0.02%

64,924

197,750,322

19. Authority to allot shares

170,146,304

86.21%

27,221,034

13.79%

382,984

197,750,322

20. To dis-apply pre-emption rights for general purposes

196,872,145

99.56%

869,023

0.44%

9,154

197,750,322

21. To dis-apply pre-emption rights for an acquisition or other capital investment

173,591,716

87.79%

24,149,939

12.21%

8,666

197,750,321

22. To authorise the Company to purchase its own shares

197,014,413

99.66%

676,265

0.34%

59,643

197,750,321

23. To authorise the Company to hold general meetings on no less than 14 clear days' notice

187,053,655

94.82%

10,213,802

5.18%

482,864

197,750,321

 

Declaration of final dividend

The dividend of 22 cents per share will be paid on 25 May 2017 to shareholders on the register on 7 April 2017.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.2898 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

VP for Investor Relations and Strategy

 

+44 20 7399 2670

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe.  In 2016, Hikma achieved revenue of $1,950 million and profit attributable to shareholders of $155 million. In the United States, Hikma operates through its wholly owned subsidiary, West-Ward Pharmaceuticals Corp., with operations based in New Jersey, Ohio and Tennessee. For more information visit www.hikma.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSFEFDUFWSELI